AKT1 and breast cancer: Mice with breast cancer driven by mutations upstream of the PI3K/Akt insulin signaling pathway are found to be responsive to dapagliflozin, while those driven by mutations downstream of PI3K/Akt or in pathways with other driver mutations did not.